Lifetime risks of common cancers among retinoblastoma survivors
- PMID: 14996857
- DOI: 10.1093/jnci/djh058
Lifetime risks of common cancers among retinoblastoma survivors
Abstract
Background: Compared with the general population, carriers of germline mutations in RB1 who survive retinoblastoma (i.e., hereditary retinoblastoma survivors) are at increased risk of early-onset second cancers, particularly sarcomas, brain tumors, and melanoma. However, their risks for the epithelial cancers that commonly occur after age 50 years are not known.
Methods: We used hospital records to identify British retinoblastoma survivors born between 1873 and 1950, a period when few British retinoblastoma patients received high-dose radiotherapy. Cancers and deaths were identified by linkage with national registration records. All statistical tests were two-sided.
Results: We could trace the cancer histories of 144 survivors of hereditary retinoblastoma. From age 25 to age 84, there were 58 subsequent cancers, for a cumulative cancer incidence of 68.8% (95% confidence interval [CI] = 48.0% to 87.4%) and a cumulative cancer mortality of 56.3% (95% CI = 40.5% to 73.3%). Only eight of the 58 cancers were of bone or soft tissue, in marked contrast to findings from contemporary studies of American patients treated with external beam radiotherapy, among whom most second tumors are sarcomas. Compared with the general population, hereditary retinoblastoma survivors had higher mortality from lung cancer (standardized mortality ratio [SMR] = 7.01, 95% CI = 3.83 to 11.76), bladder cancer (SMR = 26.31, 95% CI = 8.54 to 61.41), and all other epithelial cancers combined (SMR = 3.29, 95% CI = 1.64 to 5.89). The overall standardized mortality ratio for epithelial cancer was inversely proportional to the approximate square of age (exponent of age = -2.1, 95% CI = -3.6 to -0.7), declining from 11.32 (95% CI = 4.15 to 24.64) at age 25-44 to 2.83 (95% CI = 1.04 to 6.16) at age 65-84.
Conclusions: Survivors of hereditary retinoblastoma who are not exposed to high-dose radiotherapy have a high lifetime risk of developing a late-onset epithelial cancer. Most of the excess cancer risks in hereditary retinoblastoma survivors might be preventable by limiting exposures to DNA damaging agents (radiotherapy, tobacco, and UV light).
Comment in
-
For whom the bell tolls: susceptibility to common adult cancers in retinoblastoma survivors.J Natl Cancer Inst. 2004 Mar 3;96(5):342-3. doi: 10.1093/jnci/djh080. J Natl Cancer Inst. 2004. PMID: 14996847 No abstract available.
Similar articles
-
Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.J Natl Cancer Inst. 2008 Dec 17;100(24):1771-9. doi: 10.1093/jnci/djn394. Epub 2008 Dec 9. J Natl Cancer Inst. 2008. PMID: 19066271
-
Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma.J Natl Cancer Inst. 2007 Jan 3;99(1):24-31. doi: 10.1093/jnci/djk002. J Natl Cancer Inst. 2007. PMID: 17202110
-
Cause-specific mortality in long-term survivors of retinoblastoma.J Natl Cancer Inst. 2009 Apr 15;101(8):581-91. doi: 10.1093/jnci/djp046. Epub 2009 Apr 7. J Natl Cancer Inst. 2009. PMID: 19351917 Free PMC article.
-
Second primary tumors in patients with retinoblastoma. A review of the literature.Ophthalmic Genet. 1997 Mar;18(1):27-34. doi: 10.3109/13816819709057880. Ophthalmic Genet. 1997. PMID: 9134547 Review.
-
Second nonocular tumors in survivors of heritable retinoblastoma and prior radiation therapy.Am J Ophthalmol. 1998 Aug;126(2):269-77. doi: 10.1016/s0002-9394(98)00146-9. Am J Ophthalmol. 1998. PMID: 9727521 Review.
Cited by
-
Retinoblastoma: concerning its initiation and treatment.Int J Ophthalmol. 2013 Jun 18;6(3):397-401. doi: 10.3980/j.issn.2222-3959.2013.03.26. Print 2013. Int J Ophthalmol. 2013. PMID: 23826540 Free PMC article.
-
Targeting Hsp90 in urothelial carcinoma.Oncotarget. 2015 Apr 20;6(11):8454-73. doi: 10.18632/oncotarget.3502. Oncotarget. 2015. PMID: 25909217 Free PMC article. Review.
-
Variation of second cancer risk by family history of retinoblastoma among long-term survivors.J Clin Oncol. 2012 Mar 20;30(9):950-7. doi: 10.1200/JCO.2011.37.0239. Epub 2012 Feb 21. J Clin Oncol. 2012. PMID: 22355046 Free PMC article.
-
Melanoma: from mutations to medicine.Genes Dev. 2012 Jun 1;26(11):1131-55. doi: 10.1101/gad.191999.112. Genes Dev. 2012. PMID: 22661227 Free PMC article. Review.
-
Current management strategies for intraocular retinoblastoma.Drugs. 2007;67(15):2173-85. doi: 10.2165/00003495-200767150-00005. Drugs. 2007. PMID: 17927283 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous